The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) affects 43,000 women worldwide every year and has a five-year survival rate of 30%. Mainstay treatment is extensive surgery and chemotherapy. Outcomes could be improved by molecular profiling. We conducted a review of the literature to identify relevant publications o...
Gespeichert in:
Veröffentlicht in: | Journal of clinical medicine 2020-07, Vol.9 (7), p.2239 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 7 |
container_start_page | 2239 |
container_title | Journal of clinical medicine |
container_volume | 9 |
creator | Dion, Ludivine Carton, Isis Jaillard, Sylvie Nyangoh Timoh, Krystel Henno, Sébastien Sardain, Hugo Foucher, Fabrice Levêque, Jean de la Motte Rouge, Thibault Brousse, Susie Lavoué, Vincent |
description | Epithelial ovarian cancer (EOC) affects 43,000 women worldwide every year and has a five-year survival rate of 30%. Mainstay treatment is extensive surgery and chemotherapy. Outcomes could be improved by molecular profiling. We conducted a review of the literature to identify relevant publications on molecular and genetic alterations in EOC. Approximately 15% of all EOCs are due to BRCA1 or BRCA2 mutations. Four histologic subtypes characterized by different mutations have been described: serous, endometrioid, mucinous, and clear-cell. Between 20–30% of high-grade serous EOCs have a BRCA mutation. Tumors with BRCA mutations are unable to repair double-strand DNA breaks, making them more sensitive to platinum-based chemotherapy and to PolyAdenosine Diphosphate-Ribose Polymerase (PARP) inhibitors. Olaparib is a PARP inhibitor with proven efficacy in BRCA-mutated ovarian cancer, but its effectiveness remains to be demonstrated in tumors with a BRCAness (breast cancer) profile (i.e., also including sporadic tumors in patients with deficient DNA repair genes). A universally accepted molecular definition of BRCAness is required to identify optimal theranostic strategies involving PARP inhibitors. Gene expression analyses have led to the identification of four subgroups of high-grade serous EOC: mesenchymal, proliferative, differentiated, and immunoreactive. These subtypes are not mutually exclusive but are correlated with prognosis. They are not yet used in routine clinical practice. A greater understanding of EOC subtypes could improve patient management. |
doi_str_mv | 10.3390/jcm9072239 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7408825</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2424995518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-80cd5b6826a88c190a12e3cf2ff7e2b922ed82a8d9d38321472265143d013c683</originalsourceid><addsrcrecordid>eNpdUUtrGzEQFiWhCUku_QWCXpqCW2mk1UqXQDB5gUt6SI9FyFptLaOVNtKuIf--Mg59ZC7zMfPNNy-EPlDyhTFFvm7toEgLwNQ7dAqkbReESXb0Dz5BF6VsSTUpOdD2PTphIFolhDpFP582Dq9M7Io1o8MV4BrJFc-Tt_hhGIO3ZvIpFpx6_C0FZ-dgMv6eU--DK9hHfDP6aeOCNwE_7kz2JuKlidblc3Tcm1Dcxas_Qz9ub56W94vV493D8nq1sJy200IS2zVrIUEYKS1VxFBwzPbQ962DtQJwnQQjO9XVfYDyuq9oKGcdocwKyc7Q1UF3nNeD66yLUzZBj9kPJr_oZLz-PxP9Rv9KO93yehRoqsDlQWDzpuz-eqX3MQIKJOewo5X76bVZTs-zK5MefLEuBBNdmosGDlyppqH7uT6-oW7TnGM9hQbBKRHACKmszweWzamU7Po_E1Ci90_Wf5_MfgMXpJbY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2641062300</pqid></control><display><type>article</type><title>The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Dion, Ludivine ; Carton, Isis ; Jaillard, Sylvie ; Nyangoh Timoh, Krystel ; Henno, Sébastien ; Sardain, Hugo ; Foucher, Fabrice ; Levêque, Jean ; de la Motte Rouge, Thibault ; Brousse, Susie ; Lavoué, Vincent</creator><creatorcontrib>Dion, Ludivine ; Carton, Isis ; Jaillard, Sylvie ; Nyangoh Timoh, Krystel ; Henno, Sébastien ; Sardain, Hugo ; Foucher, Fabrice ; Levêque, Jean ; de la Motte Rouge, Thibault ; Brousse, Susie ; Lavoué, Vincent</creatorcontrib><description>Epithelial ovarian cancer (EOC) affects 43,000 women worldwide every year and has a five-year survival rate of 30%. Mainstay treatment is extensive surgery and chemotherapy. Outcomes could be improved by molecular profiling. We conducted a review of the literature to identify relevant publications on molecular and genetic alterations in EOC. Approximately 15% of all EOCs are due to BRCA1 or BRCA2 mutations. Four histologic subtypes characterized by different mutations have been described: serous, endometrioid, mucinous, and clear-cell. Between 20–30% of high-grade serous EOCs have a BRCA mutation. Tumors with BRCA mutations are unable to repair double-strand DNA breaks, making them more sensitive to platinum-based chemotherapy and to PolyAdenosine Diphosphate-Ribose Polymerase (PARP) inhibitors. Olaparib is a PARP inhibitor with proven efficacy in BRCA-mutated ovarian cancer, but its effectiveness remains to be demonstrated in tumors with a BRCAness (breast cancer) profile (i.e., also including sporadic tumors in patients with deficient DNA repair genes). A universally accepted molecular definition of BRCAness is required to identify optimal theranostic strategies involving PARP inhibitors. Gene expression analyses have led to the identification of four subgroups of high-grade serous EOC: mesenchymal, proliferative, differentiated, and immunoreactive. These subtypes are not mutually exclusive but are correlated with prognosis. They are not yet used in routine clinical practice. A greater understanding of EOC subtypes could improve patient management.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm9072239</identifier><identifier>PMID: 32679669</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Anemia ; Breast cancer ; Cancer therapies ; Cell cycle ; Chemotherapy ; Classification ; Clinical medicine ; Clinical trials ; DNA methylation ; Genes ; Kinases ; Life Sciences ; Medical prognosis ; Mutation ; Ovarian cancer ; Review ; Surgery ; Tumors ; Womens health</subject><ispartof>Journal of clinical medicine, 2020-07, Vol.9 (7), p.2239</ispartof><rights>2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-80cd5b6826a88c190a12e3cf2ff7e2b922ed82a8d9d38321472265143d013c683</citedby><cites>FETCH-LOGICAL-c417t-80cd5b6826a88c190a12e3cf2ff7e2b922ed82a8d9d38321472265143d013c683</cites><orcidid>0000-0001-7311-156X ; 0000-0001-8914-5756 ; 0000-0002-4682-2806 ; 0000-0003-4587-3828</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408825/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408825/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://hal.science/hal-02928442$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Dion, Ludivine</creatorcontrib><creatorcontrib>Carton, Isis</creatorcontrib><creatorcontrib>Jaillard, Sylvie</creatorcontrib><creatorcontrib>Nyangoh Timoh, Krystel</creatorcontrib><creatorcontrib>Henno, Sébastien</creatorcontrib><creatorcontrib>Sardain, Hugo</creatorcontrib><creatorcontrib>Foucher, Fabrice</creatorcontrib><creatorcontrib>Levêque, Jean</creatorcontrib><creatorcontrib>de la Motte Rouge, Thibault</creatorcontrib><creatorcontrib>Brousse, Susie</creatorcontrib><creatorcontrib>Lavoué, Vincent</creatorcontrib><title>The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer</title><title>Journal of clinical medicine</title><description>Epithelial ovarian cancer (EOC) affects 43,000 women worldwide every year and has a five-year survival rate of 30%. Mainstay treatment is extensive surgery and chemotherapy. Outcomes could be improved by molecular profiling. We conducted a review of the literature to identify relevant publications on molecular and genetic alterations in EOC. Approximately 15% of all EOCs are due to BRCA1 or BRCA2 mutations. Four histologic subtypes characterized by different mutations have been described: serous, endometrioid, mucinous, and clear-cell. Between 20–30% of high-grade serous EOCs have a BRCA mutation. Tumors with BRCA mutations are unable to repair double-strand DNA breaks, making them more sensitive to platinum-based chemotherapy and to PolyAdenosine Diphosphate-Ribose Polymerase (PARP) inhibitors. Olaparib is a PARP inhibitor with proven efficacy in BRCA-mutated ovarian cancer, but its effectiveness remains to be demonstrated in tumors with a BRCAness (breast cancer) profile (i.e., also including sporadic tumors in patients with deficient DNA repair genes). A universally accepted molecular definition of BRCAness is required to identify optimal theranostic strategies involving PARP inhibitors. Gene expression analyses have led to the identification of four subgroups of high-grade serous EOC: mesenchymal, proliferative, differentiated, and immunoreactive. These subtypes are not mutually exclusive but are correlated with prognosis. They are not yet used in routine clinical practice. A greater understanding of EOC subtypes could improve patient management.</description><subject>Anemia</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Chemotherapy</subject><subject>Classification</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>DNA methylation</subject><subject>Genes</subject><subject>Kinases</subject><subject>Life Sciences</subject><subject>Medical prognosis</subject><subject>Mutation</subject><subject>Ovarian cancer</subject><subject>Review</subject><subject>Surgery</subject><subject>Tumors</subject><subject>Womens health</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdUUtrGzEQFiWhCUku_QWCXpqCW2mk1UqXQDB5gUt6SI9FyFptLaOVNtKuIf--Mg59ZC7zMfPNNy-EPlDyhTFFvm7toEgLwNQ7dAqkbReESXb0Dz5BF6VsSTUpOdD2PTphIFolhDpFP582Dq9M7Io1o8MV4BrJFc-Tt_hhGIO3ZvIpFpx6_C0FZ-dgMv6eU--DK9hHfDP6aeOCNwE_7kz2JuKlidblc3Tcm1Dcxas_Qz9ub56W94vV493D8nq1sJy200IS2zVrIUEYKS1VxFBwzPbQ962DtQJwnQQjO9XVfYDyuq9oKGcdocwKyc7Q1UF3nNeD66yLUzZBj9kPJr_oZLz-PxP9Rv9KO93yehRoqsDlQWDzpuz-eqX3MQIKJOewo5X76bVZTs-zK5MefLEuBBNdmosGDlyppqH7uT6-oW7TnGM9hQbBKRHACKmszweWzamU7Po_E1Ci90_Wf5_MfgMXpJbY</recordid><startdate>20200715</startdate><enddate>20200715</enddate><creator>Dion, Ludivine</creator><creator>Carton, Isis</creator><creator>Jaillard, Sylvie</creator><creator>Nyangoh Timoh, Krystel</creator><creator>Henno, Sébastien</creator><creator>Sardain, Hugo</creator><creator>Foucher, Fabrice</creator><creator>Levêque, Jean</creator><creator>de la Motte Rouge, Thibault</creator><creator>Brousse, Susie</creator><creator>Lavoué, Vincent</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7311-156X</orcidid><orcidid>https://orcid.org/0000-0001-8914-5756</orcidid><orcidid>https://orcid.org/0000-0002-4682-2806</orcidid><orcidid>https://orcid.org/0000-0003-4587-3828</orcidid></search><sort><creationdate>20200715</creationdate><title>The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer</title><author>Dion, Ludivine ; Carton, Isis ; Jaillard, Sylvie ; Nyangoh Timoh, Krystel ; Henno, Sébastien ; Sardain, Hugo ; Foucher, Fabrice ; Levêque, Jean ; de la Motte Rouge, Thibault ; Brousse, Susie ; Lavoué, Vincent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-80cd5b6826a88c190a12e3cf2ff7e2b922ed82a8d9d38321472265143d013c683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Anemia</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Chemotherapy</topic><topic>Classification</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>DNA methylation</topic><topic>Genes</topic><topic>Kinases</topic><topic>Life Sciences</topic><topic>Medical prognosis</topic><topic>Mutation</topic><topic>Ovarian cancer</topic><topic>Review</topic><topic>Surgery</topic><topic>Tumors</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dion, Ludivine</creatorcontrib><creatorcontrib>Carton, Isis</creatorcontrib><creatorcontrib>Jaillard, Sylvie</creatorcontrib><creatorcontrib>Nyangoh Timoh, Krystel</creatorcontrib><creatorcontrib>Henno, Sébastien</creatorcontrib><creatorcontrib>Sardain, Hugo</creatorcontrib><creatorcontrib>Foucher, Fabrice</creatorcontrib><creatorcontrib>Levêque, Jean</creatorcontrib><creatorcontrib>de la Motte Rouge, Thibault</creatorcontrib><creatorcontrib>Brousse, Susie</creatorcontrib><creatorcontrib>Lavoué, Vincent</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dion, Ludivine</au><au>Carton, Isis</au><au>Jaillard, Sylvie</au><au>Nyangoh Timoh, Krystel</au><au>Henno, Sébastien</au><au>Sardain, Hugo</au><au>Foucher, Fabrice</au><au>Levêque, Jean</au><au>de la Motte Rouge, Thibault</au><au>Brousse, Susie</au><au>Lavoué, Vincent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer</atitle><jtitle>Journal of clinical medicine</jtitle><date>2020-07-15</date><risdate>2020</risdate><volume>9</volume><issue>7</issue><spage>2239</spage><pages>2239-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Epithelial ovarian cancer (EOC) affects 43,000 women worldwide every year and has a five-year survival rate of 30%. Mainstay treatment is extensive surgery and chemotherapy. Outcomes could be improved by molecular profiling. We conducted a review of the literature to identify relevant publications on molecular and genetic alterations in EOC. Approximately 15% of all EOCs are due to BRCA1 or BRCA2 mutations. Four histologic subtypes characterized by different mutations have been described: serous, endometrioid, mucinous, and clear-cell. Between 20–30% of high-grade serous EOCs have a BRCA mutation. Tumors with BRCA mutations are unable to repair double-strand DNA breaks, making them more sensitive to platinum-based chemotherapy and to PolyAdenosine Diphosphate-Ribose Polymerase (PARP) inhibitors. Olaparib is a PARP inhibitor with proven efficacy in BRCA-mutated ovarian cancer, but its effectiveness remains to be demonstrated in tumors with a BRCAness (breast cancer) profile (i.e., also including sporadic tumors in patients with deficient DNA repair genes). A universally accepted molecular definition of BRCAness is required to identify optimal theranostic strategies involving PARP inhibitors. Gene expression analyses have led to the identification of four subgroups of high-grade serous EOC: mesenchymal, proliferative, differentiated, and immunoreactive. These subtypes are not mutually exclusive but are correlated with prognosis. They are not yet used in routine clinical practice. A greater understanding of EOC subtypes could improve patient management.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>32679669</pmid><doi>10.3390/jcm9072239</doi><orcidid>https://orcid.org/0000-0001-7311-156X</orcidid><orcidid>https://orcid.org/0000-0001-8914-5756</orcidid><orcidid>https://orcid.org/0000-0002-4682-2806</orcidid><orcidid>https://orcid.org/0000-0003-4587-3828</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2077-0383 |
ispartof | Journal of clinical medicine, 2020-07, Vol.9 (7), p.2239 |
issn | 2077-0383 2077-0383 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7408825 |
source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
subjects | Anemia Breast cancer Cancer therapies Cell cycle Chemotherapy Classification Clinical medicine Clinical trials DNA methylation Genes Kinases Life Sciences Medical prognosis Mutation Ovarian cancer Review Surgery Tumors Womens health |
title | The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T18%3A32%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Landscape%20and%20Therapeutic%20Implications%20of%20Molecular%20Profiles%20in%20Epithelial%20Ovarian%20Cancer&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Dion,%20Ludivine&rft.date=2020-07-15&rft.volume=9&rft.issue=7&rft.spage=2239&rft.pages=2239-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm9072239&rft_dat=%3Cproquest_pubme%3E2424995518%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2641062300&rft_id=info:pmid/32679669&rfr_iscdi=true |